comparemela.com

Latest Breaking News On - Jacques bouchy - Page 5 : comparemela.com

Yumanity Therapeutics : Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Form 8-K

Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 . | May 11, 2023

Myriam chalabiMichaela curranPatricia lorussoShawn iadonatoJohn mullalyEvany yuJacques bouchyLifesci advisorsKineta incNetherlands cancer instituteClinical research divisionFred hutchinson cancer consortiumInvestor relations business developmentClinical researchFred hutchinson cancer centerDosed first patient

Yumanity Therapeutics : Regulation FD Presentation - Form 8-K

Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023 SEATTLE, April 17, 2023 - Kineta, Inc. , a clinical-stage. | April 17, 2023

United statesJacques bouchyThierry guillaudeuxJohn mullalyKineta incExchange commissionAmerican association for cancer researchLifesci advisorsInvestor relations business developmentKineta unveils newTrial updateAmerican associationCancer researchAnnual meetingChief scientific officerTherapeutic benefit

Yumanity Therapeutics : VISTA blocking immunotherapy engineered to address immunosuppression in the tumor microenvironment (TME) Phase 1 initial data readout anticipated by end of 2023 - Form 8-K

Kineta, Inc. , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the first patient has been. | April 12, 2023

United statesShawn iadonatoEvan yuJacques bouchyJohn mullalyExchange commissionClinical research divisionKineta incFred hutchinson cancer centerLifesci advisorsInvestor relations business developmentSection headCancer medicinePrincipal investigatorChief executive officerPrivate securities litigation reform act

Kineta to Present at the Oppenheimer 33rd Annual Healthcare

SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel.

John mullalyJacques bouchyShawn iadonatoExchange commissionLifesci advisorsKineta incInvestor relations business developmentChief executive officerAnnual healthcare conferencePrivate securities litigation reform actCurrent reportBusiness developmentSci advisorsNasdaq ka

Kineta to Host Key Opinion Leader Event on KVA12123: VISTA

SEATTLE, March 06, 2023 (GLOBE NEWSWIRE) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation.

United statesJohn mullalyJamesp allisonMichaela curranJacques bouchyPatricia lorussoDo yale school of medicine cancer centerKineta incPhasei clinical trials programAmerican cancer society levy fellowshipMemorial sloan kettering cancer centerEisenberg centerLifesci advisorsCancer centerYale cancer centerInvestor relations business development

vimarsana © 2020. All Rights Reserved.